A Clinical Study to Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
Latest Information Update: 09 Sep 2024
At a glance
- Drugs Empagliflozin (Primary) ; Ezetimibe/rosuvastatin (Primary)
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Hyundai Pharmaceutical
- 09 Sep 2024 New trial record